Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors.
about
Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesCardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balancePrimer: managing NSAID-induced ulcer complications--balancing gastrointestinal and cardiovascular risksAdherence to guidelines for avoiding drug interactions associated with warfarin--a Nationwide Swedish Register StudyPolypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolismPrescribing warfarin appropriately to meet patient safety goals.Drug-drug interactions and risk of bleeding among inpatients on warfarin therapy: a prospective observational studyOral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project)Warfarin-associated bleeding events and concomitant use of potentially interacting medicines reported to the Norwegian spontaneous reporting systemA population-based study of the drug interaction between proton pump inhibitors and clopidogrelPharmacy students' retention of knowledge of drug-drug interactionsAn evidence-based update on nonsteroidal anti-inflammatory drugs.The impact of pharmacist-managed oral anticoagulation therapy in older veterans.Inappropriate prescribing in the elderly.Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults.A potential role for avocado- and soybean-based nutritional supplements in the management of osteoarthritis: a review.Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure.Drug and dietary interactions of warfarin and novel oral anticoagulants: an update.Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis.Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents.Oral anticoagulant-associated intracerebral hemorrhage.Bleeding risk assessment in patients with atrial fibrillation who are taking oral anticoagulants.Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation.Co-Prescribing of Potentially Interacting Drugs during Warfarin Therapy - A Population-Based Register Study.High risk use of OTC NSAIDs and ASA in family medicine: A retrospective chart review.Management of NSAID-associated peptic ulcer disease.Rates of Nonsteroidal Anti-Inflammatory Drug Use in Patients with Established Cardiovascular Disease: A Retrospective, Cross-Sectional Study from NHANES 2009-2010.Prevalence of Drug Combinations Increasing Bleeding Risk Among Warfarin Users With and Without Alzheimer's Disease.The importance of monitoring adverse drug reactions in elderly patients: the results of a long-term pharmacovigilance programme.Gastrointestinal safety of nonsteroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors in patients on warfarin.The effect of drug interactions on bleeding risk associated with warfarin therapy in hospitalized patients.Drug interactions with phenprocoumon and the risk of serious haemorrhage: a nested case-control study in a large population-based German database.Macrolide-induced digoxin toxicity: a population-based study.Bleeding complications in patients on celecoxib and warfarin.Does celecoxib potentiate the anticoagulant effect of warfarin? A randomized, double-blind, controlled trial.Anticoagulation for Stroke Prevention in Older Adults with Atrial Fibrillation and Comorbidity: Current Evidence and Treatment Challenges
P2860
Q24632951-FDEEE099-19FB-4E30-BAE5-0EACB1FABF55Q28191924-76336B36-234A-4120-B93F-5A694C50F0ADQ28200571-E5FB8421-A6E2-4CDE-93B4-F0CD12E53BEDQ28538870-5AF10793-277F-41A9-8A19-7C7B0835E4D4Q33417203-E50EECBF-F5E5-4CFA-80D0-53578C21279AQ33932089-689549CE-087F-4B28-9E00-59A1239ACF53Q34228198-324B84FC-58CA-4FB2-94E0-C9BBE38F0975Q34252907-7444E5B3-DDB3-4665-8304-B1ECEE5465F0Q34310573-5C58DCF0-B17A-4B51-B521-DA2E9270E0FBQ34580625-410E88E0-7130-4DF4-B6B6-A6D2DC8AC698Q34603772-3DE1A703-F108-4926-99C9-40E8BAAC6E3CQ35220138-CFD25F72-E082-41B0-8843-DE768DB3B74EQ35758411-44B8E03B-875E-473F-AC12-6CDEA96C9951Q36730771-574E58C4-E8B8-4B02-9101-F0D5EC368423Q36768389-16C7F167-C963-4E92-9D89-20F8925E57B5Q37015862-49A046D0-8E0C-4792-B8A8-6A196EBC12B2Q37772730-C5000E60-362C-42F1-9E25-F93BADEF25DBQ37832976-D188E4E1-F68D-4F2B-8126-DDE05D50FDE5Q37848142-1F9EE226-188E-4242-A35B-0D046FB4E3D9Q37868373-EB515E39-F7C7-47F7-9BA4-DC6DAA76F375Q37897674-92DFA5F7-5A0A-4FE3-8E97-13F0B3FC141DQ37900185-9CC723B0-07FE-4DB8-AA1A-1D976FD2E84FQ38087193-11282639-AE6E-4B0E-84AC-1E34B77D2CC0Q38132255-906A8D46-B84D-45F2-A7E1-55BF4EDF0B2AQ38417110-C23DF5B3-1DFA-48D2-8205-134369A8DA22Q38693356-9CFAA94E-0DD2-4203-AF9E-1C49E6C7C0AAQ38699305-34766DAF-A2D3-44B6-87A0-918C1F794AE8Q40073885-98C490B6-CA46-4153-B1D7-16CA0BF2A824Q40420203-BE207F68-3151-4F75-BC32-2AE913869C42Q40907461-B1FF860F-2BEA-4328-97EC-D20D73800DE2Q43266149-F944B966-6B78-404F-9D99-45303FD42A84Q43285101-0D2AE77F-5EF5-41DF-ABE9-C762D57C10C7Q44848854-E7DDC0C6-7AE8-4F94-8799-A52F64270880Q45928209-95E4D01B-80A7-4543-BFD3-F9D359265EBEQ46704739-7A0DCFCA-520D-46F4-8BC4-C4334F40BD07Q51938849-2EDF437E-75B0-4CCF-93EA-A7FECE77562DQ58749820-D22E2ACC-61DC-4274-8885-768D974604C9
P2860
Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Risk of upper gastrointestinal ...... ve NSAIDs or COX-2 inhibitors.
@en
Risk of upper gastrointestinal ...... ve NSAIDs or COX-2 inhibitors.
@nl
type
label
Risk of upper gastrointestinal ...... ve NSAIDs or COX-2 inhibitors.
@en
Risk of upper gastrointestinal ...... ve NSAIDs or COX-2 inhibitors.
@nl
prefLabel
Risk of upper gastrointestinal ...... ve NSAIDs or COX-2 inhibitors.
@en
Risk of upper gastrointestinal ...... ve NSAIDs or COX-2 inhibitors.
@nl
P2093
P1476
Risk of upper gastrointestinal ...... ve NSAIDs or COX-2 inhibitors.
@en
P2093
Andreas Laupacis
David N Juurlink
Linda Rabeneck
Marisa Battistella
Muhammad M Mamdami
P304
P356
10.1001/ARCHINTE.165.2.189
P407
P577
2005-01-01T00:00:00Z